ADPT 01
Alternative Names: ADPT-01Latest Information Update: 07 Mar 2022
At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer
Most Recent Events
- 11 Aug 2021 Novartis plans to submit regulatory applications for Colorectal cancer (Combination therapy) in or after 2026 (Novartis pipeline, February 2022)
- 11 Aug 2021 Phase-I clinical trials in Colorectal cancer (Combination therapy) in Switzerland (unspecified route) before August 2021
- 10 Aug 2021 Preclinical development in Colorectal cancer (Combination therapy) in Switzerland (unspecified route) before August 2021